Regeneron: Big Pipeline with Big Potential, But Priced into Stock

SunTrust Robinson Humphrey’s Yatin Suneja says Regeneron Pharmaceuticals (REGN) is “one of the most innovative large-cap biotechs developing therapies for serious conditions.” But the sell-side analyst initiated coverage on the stock at a neutral, arguing that the drug maker is fairly valued. As he writes: Its flagship product Eylea is the leading branded anti-VEGF therapy […]